About Cellectar Biosciences, Inc.
https://www.cellectar.comCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
CEO
James V. Caruso
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-24 | Reverse | 1:30 |
| 2022-07-22 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MARXE AUSTIN W & GREENHOUSE DAVID M
Shares:2.21M
Value:$8.27M
BLACKROCK INC.
Shares:228.93K
Value:$857.34K
QS INVESTORS, LLC
Shares:142.4K
Value:$533.29K
Summary
Showing Top 3 of 11
About Cellectar Biosciences, Inc.
https://www.cellectar.comCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.8M ▼ | $-4.44M ▲ | 0% | $-1.41 ▲ | $-4.39M ▲ |
| Q2-2025 | $0 | $6.04M ▼ | $-5.45M ▲ | 0% | $-3.39 ▲ | $-5.98M ▲ |
| Q1-2025 | $0 | $6.4M ▼ | $-6.6M ▼ | 0% | $-4.3 ▼ | $-6.34M ▲ |
| Q4-2024 | $0 | $12.74M ▼ | $-2.36M ▲ | 0% | $-1.68 ▲ | $-12.68M ▲ |
| Q3-2024 | $0 | $13.33M | $-14.66M | 0% | $-11.18 | $-13.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $12.55M ▲ | $14.63M ▲ | $5.25M ▼ | $9.38M ▲ |
| Q2-2025 | $11.04M ▼ | $13.7M ▼ | $6.23M ▼ | $7.47M ▼ |
| Q1-2025 | $13.91M ▼ | $16.04M ▼ | $7.79M ▼ | $8.25M ▼ |
| Q4-2024 | $23.29M ▼ | $25.47M ▼ | $11.18M ▼ | $14.29M ▼ |
| Q3-2024 | $34.26M | $37.29M | $22.13M | $15.16M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.44M ▲ | $-4.28M ▲ | $0 | $5.79M ▲ | $1.51M ▲ | $-4.28M ▲ |
| Q2-2025 | $-5.45M ▲ | $-5.12M ▲ | $0 | $2.25M ▲ | $-2.86M ▲ | $-5.12M ▲ |
| Q1-2025 | $-6.6M ▼ | $-9.38M ▲ | $0 ▲ | $0 | $-9.38M ▲ | $-9.38M ▲ |
| Q4-2024 | $-2.36M ▲ | $-10.91M ▼ | $-61.29K ▼ | $0 ▼ | $-10.97M ▼ | $-10.97M ▼ |
| Q3-2024 | $-14.66M | $-9.17M | $0 | $17.56M | $8.39M | $-9.17M |
CEO
James V. Caruso
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-24 | Reverse | 1:30 |
| 2022-07-22 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MARXE AUSTIN W & GREENHOUSE DAVID M
Shares:2.21M
Value:$8.27M
BLACKROCK INC.
Shares:228.93K
Value:$857.34K
QS INVESTORS, LLC
Shares:142.4K
Value:$533.29K
Summary
Showing Top 3 of 11